Boron compounds

Details Boron compounds Boron compounds

1998-08-26

2000-11-07

Vollano, Jean F

Chemistry of inorganic compounds

Boron or compound thereof

Hydrogen and metal or ammonium containing

568 5, 568 6, 423276, 423278, 423283, C01B 615, C07F 502

Patent

active

061432644

DESCRIPTION:

BRIEF SUMMARY
FIELD OF THE INVENTION

The present invention relates to the preparation of boron compounds and in particular the production of substituted undecahydrododecaborate anions [B.sub.12 H.sub.11 XH].sup.2- and [B.sub.12 H.sub.(12-n) (XCN).sub.n ].sup.2-, and nonahydrodecaborate anions [B.sub.10 H.sub.9 XH].sup.2- and [B.sub.10 H.sub.(10-n) (XCN).sub.n ].sup.2- where X and n are defined herein.


BACKGROUND

Boron compounds have been used for the treatment of cancer through .sup.10 B neutron capture therapy (BNCT). Various derivatives of dodecahydrodecaborate [B.sub.12 H.sub.12 ].sup.2- and decahydrodecaborate [B.sub.10 H.sub.10 ].sup.2- have been synthesised. The sulphydryl-containing borane anion [B.sub.12 H.sub.11 SH].sup.2- (BSH) has been found to be a most suitable species for the treatment of glioma by BNCT. It is found that BSH is preferentially taken up by the brain cancer tumour (glioma), which allows selective targeting of thermal or epithermal neutrons. Presently, there is no treatment for glioma and early death of the patient is to be expected.
The compound BSH has been known for some time and is approved for therapy in the USA. A number of syntheses of BSH have been reported in the literature (W. H. Knoth, J. C. Sauer, D. C. England, W. R. Hertler and E. L. Muetterties, J. Am. Chem. Soc., 1964, 86, 3973; E. I. Tolpin, G. R. Wellum and S. A. Berly, Inorg. Chem., 1978, 17, 2867; T. Nakagawa, T. Yoshizaki and K. Aono, J. P. Kokai 75 92897 C.A. 1976 84: 79701v; M. Komura, K. Aono, K. Nagasawa and S. Sumimoto, Chem. Express, 1987, 2, 173; V. A. Brattsev and O. R. Sagitullin Pat. USSR 1328290 (1987) C.A.; 1987, 107: 179481k). However, these synthetic methods are complicated and generally involve many synthetic steps. Certain of the intermediate products may be toxic, which leads to purification problems. Finally, the overall yields are generally poor. All syntheses start from the dodecahydrododecaborate anion [B.sub.12 H.sub.12 ].sup.2- which can be obtained in high yield when decaborane is treated with triethylamine-borane (N. N. Greenwood and J. H. Morris, Proc. Chem. Soc., 1963, 338.) B.sub.10 H.sub.14 +2Et.sub.3 NBH.sub.3 .fwdarw.[Et.sub.3 NH].sub.2 [B.sub.12 H.sub.12 ]+3H.sub.2.
Alternatively, it can be obtained by the reaction: 10BH.sub.3 SMe.sub.2 +2NaBH.sub.4 .fwdarw.Na.sub.2 [B.sub.12 H.sub.12 ]+10SMe.sub.2 +13H.sub.2 (H. C. Miller, N. E. Miller and E. L. Muetterties, Inorg. Chem., 1964, 3, 1456; W. V. Hough, C. R. Guibert, and G. T. Hefferan, U.S. Pat. No. 3,961,017. C.A. 1976, 85, P126732V).
In the best reported synthesis (Komura et al., see above) seven steps are involved in converting this compound to Na.sub.2 [B.sub.12 H.sub.11 SH]. The overall yield is 68% though in practice this may represent a maximum rather than a routine achievable yield.
The syntheses of the [B.sub.12 H.sub.11 SCN].sup.2- anion, as salts with the cations [Et.sub.3 NH].sup.+, [Et.sub.4 N].sup.+, [(Ph.sub.3 P).sub.2 N].sup.+, Na.sup.+, or Cs.sup.+, are more efficient than earlier reported preparations (e.g. H. -G. Srebny and W. Preetz, Z. anorg. allg. Chem., 1984, 513, 7). Previously reported methods require the inconvenient prior preparation of (SCN).sub.2 from Pb(SCN).sub.2 and Br.sub.2, and the use of [Bu.sub.4 N].sub.2 [B.sub.12 H.sub.12 ] in CH.sub.2 Cl.sub.2. The methods of the present invention conveniently start from simple thiocyanate salts, and easily synthesised salts of [B.sub.12 H.sub.12 ].sup.2- with the cations [Et.sub.3 NH].sup.+, Na.sup.+, or K.sup.+. The reactions may also be carried out in aqueous solutions and provide quantitative yields. The compound, as its sodium salt, has excellent potential for neutron capture therapy, in view of its low biological toxicity, and good tumour-localising properties in a tumour model system.
The synthesis of the 1,7-isomer (and the 1,12-isomer as a small byproduct) of salts of [B.sub.12 H.sub.11 (SCN).sub.2 ].sup.2- have not been reported previously. Such compounds are also believed to have potential for neutron capture therapy.


SUMMARY OF THE INVENTION

It is an o

REFERENCES:
patent: 4150057 (1979-04-01), Sayles
CA:84:79701 abs of JP50092897, Dec. 1973.
CA:107:145255 abs of Acts Crystallorg Sect C: Cryst. Struct. Commun. by Nakai, H., C43(7) pp. 1420-2, 1987.
Chemistry of Boranes. XIX. Derivative Chemistry of B.sub.10 H.sub.10 .sup.-2 and B.sub.12 H.sub.12 .sup.-2, W. H. Knoth, Jr. et al., Chemistry of Boranes, Oct. 5, 1964, pp. 3973-3983.
Synthesis and Chemistry of Mercaptoundecahydro-closo-dodecaborate(2-); E. I. Tolpin et al., Inorganic Chemistry, vol. 17, No. 10, 1978, pp. 2867-2873.
Chemistry of Boranes. XX. Syntheses of Polyhedral Boranes, H. C. Miller et al., Inorganic Chemistry, vol. 3, No. 10, Oct. 1964, pp. 1456-1463.
Darstellung und Charakterisierung von Thiocyanatderivaten der Hydroboratanionen B.sub.10 H.sub.10 .sup.2- und B.sub.12 H.sub.12 .sup.2-, H. G. Srebny et al., Z. anorg.allg.Chem. 513 (1984)7-14, pp. 7-14.
A Novel Synthesis of the B.sub.12 H.sub.12 .sup.2- Anion, N. N. Greenwood et al., Proceedings of the Chemical Society, Nov. 1963, p. 338.
Dodecahydrododecaborate (2-) anions. W. V. Hough et al., 49-Industrial Inorganics, vol. 85, 1976, pp. 126754.
Method of producing cesium mercaptoundeca=hydrododecaborate, V. A. Brattsev et al., 49-Industrial Organics, vol. 107, 1987, pp. 179482.
A convenient preparation of .sup.10 B-enriched B.sub.12 H.sub.11 SH::an agent for neutron capture therapy, M. Komura et al., 107:88504d 1987, Chemabstracts.
CA:107:179481 abs of SU1328290, May 1985.
CA:103:110670 abs of Polyhedron 4(7) pp 1329-31 by Power, 1985.
CA:102:178143 abs of Bull Soc Chim Fr (11-12 pt 1) pp 336-338 by Ouassas, 1984.
Chemiche Berichte, Inorganic and Organometallic Chemistry, vol. 129, 1996, pp. 1531-1534.
Chemical Abstracts, vol. 84, No. 12, Mar. 22, 1976, Columbus, Ohio, US; Abstract No. 79701, XP002029960.

Affiliated with

Also associated with

Rating

Boron compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Boron compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Boron compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1637887